Shares of Johnson & Johnson (JNJ) - Get Report are up 1.6% Tuesday after the drug and consumer products company topped earnings per share and revenue expectations.

A sub-2% gain may not seem impressive but for a stock that's already rallied some 25% over the past year, how much more can be expected? This quarter justifies that big rally, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Dash" segment.

"It has small-cap growth for one of the largest, greatest companies on earth," Cramer said, explaining that J&J is a premium, large-cap growth stock.

"Drug after drug after drug" continues to do well, he added, pointing out notable successes such as Imbruvica, Darzalex and Xarelto. CEO Alex Gorsky has been able to deliver time and time again on the high-growth pharmaceutical business. The Tylenol and orthopedic businesses also improved, Cramer said.

Even other great large-cap companies such as Bristol-Myers Squibb (BMY) - Get Report  can't keep pace with Johnson and Johnson, he said.

So can the stock sustain its run? Once the dust settles this is an "absolutely terrific stock to own," Cramer concluded.

Image placeholder title

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.